Patients aged ≥18 years with MS from the Truven Marketscan Commercial, Medicare Supplemental and Medicaid claims databases who initiated a DMT between April 2017 and September 2019 were observed for ≥1 year pre- and post-DMT initiation. For the initiated DMT, ≥2 prescriptions were required; completing Dose 1 met this requirement for ocrelizumab. Comparator DMTs were grouped by administration route (injectable, oral or intravenous). Adherence (ie, ≥80% of days covered with supply of DMT in the post initiation year) and persistence (ie, no gap in DMT supply ≥60 days [for non-ocrelizumab DMTs] or administration of the second dose [for ocrelizumab] and no switch to another DMT in the post initiation year) were examined across groups. Relapse outcomes, healthcare resource utilization (all-cause and MS-related inpatient, outpatient and pharmacy) and non-DMT costs (all-cause and MS-related) were examined in patients determined to be adherent and persistent, respectively.

A total of 3,862 commercially insured patients (ocrelizumab, n=1,135; injectable, n=840; oral, n=1,609; intravenous, n=278) were included. Patients initiating ocrelizumab (1-year) had the highest rate of adherence (90.8%) vs other groups (injectable, 52.0%; oral, 68.4%; intravenous, 65.8%) and the lowest proportion of discontinuation (10.1% vs 44.4%, 29.3% and 27.7%, respectively). Data from the Medicare and Medicaid Supplemental populations as well as relapse and economic outcomes in adherent and persistent patient subgroups will be presented.